β淀粉样蛋白在冠心病中的研究进展  

Development of amyloid β in coronary heart disease

作　　者：田雪琴 王超[2] 冯雪 于波[2] TIAN Xue-qin;WANG Chao;FENG Xue;YU Bo(Graduate School,Harbin Medical University,Harbin 150086,Heilongjiang,China;Department of Cardiology,Second Affiliated Hospital,Harbin Medical University,Harbin 150086,Heilongjiang,China)

机构地区：[1]哈尔滨医科大学研究生院,黑龙江哈尔滨150086 [2]哈尔滨医科大学附属第二医院心内科,黑龙江哈尔滨150086

出　　处：《心脏杂志》2021年第3期317-320,共4页Chinese Heart Journal

摘　　要：冠心病(coronary heart disease, CHD)是导致心血管死亡的主要原因。生物标记物识别基于血液,可提供具有预后价值和显著再分类能力的诊疗方向,对CHD风险分层和恰当管理有很大帮助。血管炎症是CHD病理生理途径的重要组成部分。越来越多的实验和临床证据表明,β淀粉样蛋白(Aβ)作为一种具有促炎症和促血栓形成的肽,在动脉粥样硬化斑块进展中起着重要作用。该文综述了Aβ在CHD中的研究进展,提示Aβ可为CHD患者提供新型抗炎治疗靶点,具有基础与临床的指导意义。Coronary heart disease(CHD) is the main cause of cardiovascular death. Identifying bloodbased biomarkers to provide prognostic value and significant re-classification ability is of great help to risk stratification and proper management of coronary heart disease. Vascular inflammation is an important part of the pathophysiological pathway of coronary heart disease. More and more clinical evidence shows that amyloid β(aβ), as a peptide with pro-inflammatory and pro thrombogenic properties,plays an important role in the progression of atherosclerotic plaque. In this review, we summarize the research progress of amyloid β in coronary heart disease, which may provide important theoretical basis and guiding value for new anti-inflammatory treatment targets of coronary heart disease patients.

关 键 词：冠心病 Β淀粉样蛋白 炎症 

分 类 号：R541.4[医药卫生—心血管疾病]